3 March 2022 - Report will be subject of New England CEPAC meeting in September 2022; draft scoping document open ...
3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through ...
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
4 February 2022 - The field of cost effectiveness analysis has grown rapidly but in somewhat lopsided fashion. ...
3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public ...
3 February 2022 - Report will be subject of Midwest CEPAC meeting in August 2022; draft scoping document open to ...
26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
22 December 2021 - Report will be subject of CTAF meeting in July 2022; draft scoping document open to public ...
16 December 2021 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tezepelumab ...
2 December 2021 - In the multi-payer US system, each public program, private insurer, and self-insured employer conducts its own ...
24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open ...
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...